HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS)

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $7.00 target price on the stock.

Other equities research analysts have also issued research reports about the company. Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th.

Atossa Therapeutics Stock Down 2.7 %

NASDAQ:ATOS opened at $0.84 on Thursday. The firm has a 50 day moving average of $1.03 and a 200 day moving average of $1.27. The stock has a market capitalization of $105.91 million, a price-to-earnings ratio of -3.83 and a beta of 1.26. Atossa Therapeutics has a 52 week low of $0.72 and a 52 week high of $2.31.

Institutional Trading of Atossa Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC acquired a new stake in shares of Atossa Therapeutics in the third quarter worth approximately $29,000. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth about $29,000. SG Americas Securities LLC boosted its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics during the third quarter valued at about $75,000. Finally, JPMorgan Chase & Co. raised its position in Atossa Therapeutics by 177.1% in the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock valued at $227,000 after purchasing an additional 95,643 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.